Isolation, expansion and differentation of CD34+ progenitor cells
Research type
Research Study
Full title
Isolation, expansion and differentation of CD34+ progenitor cells; analysis of the cell-cell interaction and the role of the microenvironment. Incorporating process development for the production of CD34+ derived induced pluripotent stem cells.
IRAS ID
234323
Contact name
Joanne Mountford
Contact email
Sponsor organisation
KINGS COLLEG HOSPITAL
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
SNBTS currently have many donors who donate platelets and blood via a process known as apheresis, during this process rare stem cells known as haematopoietic stem progenitor cells (HSPC) or CD34+ cells, are captured in a filter which is currently discarded to waste. These rare HSPC cells have the ability to differentiate into all of the various blood cells including red cells, white cells and platelets. SNBTS researchers aim to develop protocols for the isolation and collection of these cells from this waste material. Once isolated it is intended that these cells will be examined in laboratory conditions with other cell types, such as mesenchymal stromal cells (MSC), to investigate the mechanisms of how these progenitor cells expand and how they develop into different blood cell types.
Secondly SNBTS also aims to use these recovered cells and pre and post co-culture to develop various methods to produce induced pluripotent stem cells (iPSC). Human induced pluripotent stem cells are derived from mature tissue cells or progenitor cells whose genetic clocks have been reset to turn them back into stem cells, giving them the ability to develop into almost every cell type in the body. SNBTS researchers intend to develop methods for creating iPSC cells from the recovered HSPC and their progeny pre and post culturing. These techniques will form proof of principle for producing these cells for eventual therapeutic use in patients. The iPSC lines of interest for future therapeutic use would include an iPS MSC cell line, stem-like progenitors and progeny of endothelial, RBC, liver, nerve and muscle.
Information generated from this study will help inform how normal HSPC cells develop and interact with other human cells and will also help inform how these cells might be used for producing human iPS cells for future cellular therapies.
REC name
North East - Newcastle & North Tyneside 1 Research Ethics Committee
REC reference
18/NE/0057
Date of REC Opinion
12 Feb 2018
REC opinion
Favourable Opinion